Progyny saw an improvement in its IBD SmartSelect Composite Rating Thursday, from 92 to 96.
Looking For Winning Stocks? How To Invest In Both Bull And Bear Markets
The new rating shows the stock is outpacing 96% of all stocks when it comes to the most important stock-picking criteria. The market's biggest winners often have a 95 or higher grade in the early stages of a new price run, so that's a good item to have on your checklist when looking for the best stocks to buy and watch.
Progyny is not currently near a proper buy zone. Look for the stock to form and break out of a new chart pattern.
The stock sports a 98 EPS Rating, which means its recent quarterly and longer-term annual earnings growth is outpacing 98% of all stocks.
Its Accumulation/Distribution Rating of C shows a roughly equal amount of buying and selling by institutional investors over the last 13 weeks.
The company reported 23% EPS growth for Q1. Sales growth increased 17%, up from 11% in the prior quarter. That marks two consecutive reports with increasing revenue gains.
Progyny earns the No. 3 rank among its peers in the Medical-Services industry group. Hims & Hers Health is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
